Investment
Features
FeesSafety
Academy
More
Pluang+

Polygon loses main revenue source as Polymarket plans to leave, risking network's future fees.

Protocol Fundamentals
28 Sep 2026
CryptoTicker
View Source
Bearish
Polygon loses main revenue source as Polymarket plans to leave, risking network's future fees.

Polygon, once a leading low-fee Ethereum alternative, now depends heavily on one protocol, Polymarket, which accounts for 83.6% of its $37 million monthly fees. Polymarket has announced plans to leave Polygon for its own chain, seeking better control over fees and block times. This departure threatens Polygon's main revenue stream, leaving the network with a smaller ecosystem focused on payments, stablecoins, and tokenized collectibles. Investors should watch for Polymarket's migration date, as it will significantly impact Polygon's revenue and token value, which is currently 90.8% below its 2024 peak.

Polygon's ecosystem changes provide context for cryptocurrency market trends on Pluang. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Sep 29, 2026 00:41 WIB: out of 50 major cryptocurrencies, 11 rose and 38 fell today. Notable movers include SXP at Rp37 with a -46.27% change, ALGO at Rp2.441 with a +16.52% change and balanced order activity, and BAL at Rp16.297 with an +11.14% change and a typical hold time of 85 days.

More News

RGA stock set for 16.7% rise on strong earnings and favorable market conditions

RGA stock set for 16.7% rise on strong earnings and favorable market conditions

Morgan Stanley raised the price target for Reinsurance Group of America (RGA) to $295, implying a 16.7% upside from its current price of $252.85. The company reported a 42% increase in adjusted operating income to $746 million in H1, driven by its lo...

Analyst Insights
Bullish
52 minutes ago
Kodiak Sciences stock jumps 176% after positive Phase 3 trial for retinal disease drug

Kodiak Sciences stock jumps 176% after positive Phase 3 trial for retinal disease drug

Kodiak Sciences reported successful Phase 3 trial results for its retinal disease treatments Zenkuda and tabirafusp-ted, showing vision improvements comparable to Regeneron's Eylea. Zenkuda allowed 54% of patients to maintain a six-month dosing inter...

Market News
Bullish
2 hours ago
Citigroup keeps Neutral on Regeneron amid rising competition from Kodiak Sciences' eye drug success

Citigroup keeps Neutral on Regeneron amid rising competition from Kodiak Sciences' eye drug success

Citigroup has maintained a Neutral rating on Regeneron Pharmaceuticals due to increasing competition in the ophthalmology sector. Kodiak Sciences reported positive Phase 3 trial results for its eye drugs, challenging Regeneron's key product, Eylea, e...

Analyst Insights
Neutral
2 hours ago
Bitcoin Standard Treasury cancels SPAC deal amid market pressure, paying Cantor $15M

Bitcoin Standard Treasury cancels SPAC deal amid market pressure, paying Cantor $15M

Bitcoin Standard Treasury Company and Cantor Equity Partners I ended their planned business combination on August 20 due to market pressure reducing the appeal of public Bitcoin treasury vehicles. As part of the termination, BSTR must pay Cantor $15 ...

Market News
Bearish
4 hours ago
WisdomTree Japan Opportunities Fund ETF outperforms US indices in 2024 despite macroeconomic risks.

WisdomTree Japan Opportunities Fund ETF outperforms US indices in 2024 despite macroeconomic risks.

The WisdomTree Japan Opportunities Fund ETF (OPPJ) has outperformed major US stock indices in 2024, driven by its focus on industrials and globally diversified Japanese trading firms. However, the fund faces significant challenges due to its over 75%...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App